Introduction
Prostate-specific antigen (PSA)-based screening for prostate cancer (CaP) has resulted in a stage migration, leading patients to be diagnosed earlier in the disease process, at a younger age and with lower risk factors [1, 2] . Data from the large Cancer of the Prostate Strategic Urologic
Research Endeavor (CaPSURE) database demonstrated a significant increase in the proportion of patients with low-risk tumor characteristics from 29.8% in 1989-1992 to 45.3% in 1999-2001 [2] . More importantly, the robust favorable long-term survival in low-risk CaP has become even more pronounced in recent years because PSA testing has led to cancer diagnosis at an earlier point of the disease course and to be alive longer with their disease. In fact, progression-free survival following local intervention for low-risk CaP approaches 95% at 10 years [3] .
Various established treatment options exist for clinically localized CaP, such as active surveillance (AS), radical prostatectomy (RP), radiotherapy (RT), and brachytherapy (BT). Some of these, such as radiation therapy, can include hormonal therapy in the regimen. Unfortunately, there have been no adequately sized randomized clinical trials to directly compare the various interventions for CaP, and past attempts to compare interventions such as brachytherapy and radical prostatectomy have not been successful. Therefore, in the setting in which one treatment option cannot be ruled superior to another, the side effect profiles of the different treatment options are often considered with making a treatment decision. Understanding the health related quality of life (HRQOL) enables the urologist and individual patient to have realistic expectations and to optimize treatment decisions for the CaP patient. Customizing risk profile to each patient can also prove to be important, such as taking into consideration the patient's baseline health, anxiety, and expectations. For example, a patient who has a history of obstructive urinary symptoms related to symptomatic benign prostatic hyperplasia (BPH) may benefit from surgical treatment of his cancer, which would also alleviate his symptoms of BPH.
A summary of common interventions for CaP and associated HRQOL side effects is listed in Table 1 . Because there is limited evidence that any of the treatments for localized disease is superior to another in terms of overall survival, patients must consider other variables when choosing therapy. One of these other considerations is quality of life (QOL). Recognition of the importance of HRQOL related to the side effects of CaP treatments has grown over the years. Although the awareness by physicians and patients has increased, there is still a paucity of objective data of HRQOL for CaP treatment, primarily due to the relative lack of prospective trials. It is critically important that clinicians understand the impact of CaP and its effect on HRQOL so that they can better counsel their patients and make early interventions that improve patient outcomes. The aim of this review is to briefly establish the definition of HRQOL as well as the known consequences of CaP treatments on HRQOL, and review updates on this topic in recent literature concerning the management of localized CaP.
Definition and Measurement of HRQOL in CaP HRQOL is measured using standardized questionnaires, which collect patient-centric data and provide an objective assessment and perception of both generic and disease specific domains. In the past, health care providers would document what was perceived QOL, but a more accurate measure includes patient-driven perception of personal health, the ability to function in life, and overall sense of satisfaction with life experiences [4] . The ultimate goal of HRQOL is to detect variation in the natural history of disease and treatment effects not described by vital status or observations recorded in the clinical record [5] . There are several validated questionnaires, also commonly described as "instruments" or "tools," developed for patients with CaP.
The University of California Los Angeles Prostate Cancer Index (UCLA-PCI) was the first validated questionnaire specifically designed to measure HRQOL in localized CaP patients.
General HRQOL domains were borrowed from the established Medical Outcomes Study Short Form (SF-36), and prostate-specific domains were included: urinary function and bother, sexual function and bother, and bowel function and bother. Briefly, the SF-36, which is perhaps the most widely used tool for general HRQOL, consists of eight scaled scores: vitality, physical functioning, bodily pain, general health perceptions, physical role functioning, emotional role functioning, social role functioning, and mental health [5] .
The Expanded Prostate Cancer Index Composite (EPIC) is a comprehensive instrument designed to evaluate patient function and bother after CaP treatment. Content from the original UCLA-PCI was expanded with guidance from a cohort of localized CaP patients and an expert panel comprised of urologic oncologists, radiation oncologists, survey researchers, and CaP nurses. This extensive panel found a need to augment the UCLA-PCI with items to capture additional concerns relevant to BT, RT, RP, and androgen deprivation. Symptom-specific bother items corresponding to each symptom item were added to elicit multi-item bother scales for each HRQOL domain [4] .
The European Organization for Research and Treatment of Cancer Core Quality of Life
Questionnaire (EORTC QLQ-C30) is a 30-item self-reported questionnaire developed to assess the QOL of cancer patients. It is grouped into five functional subscales: role, physical, cognitive, emotional, and social functioning. In addition, there are three multi-item symptom scales (fatigue, pain, and nausea and vomiting), individual questions concerning common symptoms in cancer patients, and two questions assessing overall QOL. The EORTC QLQPR25 was developed to incorporate an additional 25-item subset specific to CaP [6] .
Effect of Patient Treatment Options on Patient QOL

Active Surveillance
CaP can progress slowly and, with or without treatment, a large number of men can live many years after diagnosis. The realization that low-risk CaP may sometimes be overtreated by surgery or radiation has been an impetus in the development of an active surveillance (AS) protocol. Therefore, men with favorable disease-specific features are candidates for AS, and perhaps can benefit from the avoidance of various side effects of treatment of localized CaP such as incontinence, bleeding, gastrointestinal toxicity, and erectile dysfunction. Although physical side effects may be avoided with AS, there is an emerging concern that patients may be at an increased risk of psychologic distress. HRQOL was evaluated in 129 men that were enrolled in the Prostate Cancer Research International: Active Surveillance (PRIAS) study.
Although for the most part, AS was well tolerated among the cohort, certain risk factors for patients who may not do well on AS emerged. A perception of the physician contributing to the majority of the decision making, a poor physical health score, a high neuroticism (anxiety) score, and a high PSA value all had significant positive associations with lower HRQOL scores [7] .
Burnet et al. [8] also noted that AS, as a treatment entity, did not offer higher overall psychological distress compared with other CaP treatments, but analyses indicated that higher anxiety scores were significantly associated with younger age and a longer time interval from diagnosis. In addition, higher depression scores were significantly associated with a longer interval since diagnosis (P<0.05), but not with management by AS. Therefore, although AS has substantial benefits, it can also have significant effects on QOL, and additional research is needed to define how to minimize the specific QOL domains affected. at the initial diagnosis with that of patients whose treatment is AS and selective active treatment intervention (either radiation or surgery). In addition to cancer-related outcomes, the study will use a number of QOL instruments to further examine the QOL problems these different approaches may involve [9] .
Radical Prostatectomy
Several trials have shown that RP has significant negative effect on multiple QOL consecutive patients divided into two cohorts according to the percentage of nerve sparing performed, >50% versus ≤50%, at the time of RP. Nerve sparing was associated with better urinary function (P=0.014) and urinary bother (P=0.043). After adjusting for preoperative variables, the increased NSP group scored 8.4 points higher for urinary function and 8.5 points higher for urinary bother compared with the non-NSP group. Long-term (>5 years) improvement in urinary incontinence was seen in the NSP group by Nandipati et al. [17] .
Urinary continence status was defined as completely pad-free or wearing a single pad for protection (dry pad). Overall incontinence rate was reported to be higher in the non-NS than the bilateral NS (29.5% vs 9.1%, respectively; P<0.05). Return of incontinence was also significantly quicker in the bilateral NS group. Although several anecdotal opinions exist, such as a more meticulous apical dissection at the time of NSP and more careful overall technique, the exact causal mechanism of NSP in improving urinary function is not known.
Radiotherapy of the Prostate
Patients undergoing RT for localized CaP can have urinary, sexual, and gastrointestinal tract dysfunction after treatment. However, the symptomatology of urinary dysfunction after RT is different than that of patients who undergo surgery. Unlike surgery, which can result in stress urinary incontinence, RT can result in irritative voiding symptoms, such as urgency, frequency, and urge incontinence, that negatively affect overall urinary function and HRQOL. Also, specific to RT is a higher incidence bowel irritation. BT and RT were both associated with a reduced QOL related to bowel function early after treatment, continuing in some patients for more than a year. Sanda et al. [11••] reported rectal urgency, frequency, pain, fecal incontinence, or hematochezia-caused distress related to bowel function in 9% of patients a year after RT. The most predominant severe acute toxicity after BT is urinary retention requiring catheterization [18] . In fact, Roeloffzen et al. [18] reported that acute urinary retention after prostate BT has a significant negative impact on patients' HRQOL up to 6 years after treatment, in terms of both global QOL measures and urinary symptom scores. Proper selection of patients can minimize the risk of retention following BT.
Postoperative RT for CaP in a salvage or an adjuvant setting presents a unique challenge, in that maximizing urinary continence and potency prior to delivery of RT is of concern.
Pinkawa et al. [19] indicating, despite the increased awareness in literature, a need for further provider awareness on QOL issues. As the time from primary treatment increased, patients did report less impairment in all domains, but physicians recorded more improvement than did their patients. This study clearly shows that the wide gap continues to exist between the HRQOL that patients report and that which their physicians assess.
Impact of Screening and Diagnosis on HRQOL
PSA screening and monitoring can adversely affect patients' anxiety levels and therefore have a diminutive effect on their QOL. Even prior to being diagnosed with CaP, there can be mental anguish and anxiety resulting in a decreased QOL from CaP screening. Carlsson et al. [21] evaluated the anxiety levels of nearly 1800 men with PSA ≥3 ng/mL partaking in the European Randomized Study of Screening for Prostate Cancer. The study illustrated that most men have low to moderate anxiety while waiting for further clinical examination for an elevated PSA, and that <5% of men reported high levels of anxiety. Despite the high sensitivity of PSA, variable factors can falsely elevate PSA, including benign enlargement of the prostate. Katz et al. [22] evaluated the effect on psychological well-being of 109 men with an abnormal PSA test or an abnormal digital rectal examination (DRE) but a negative biopsy result. Men with abnormal CaP screening tests report increased cancer related worry and more problems with sexual function, despite having a negative biopsy result. Therefore, false positive results may contribute to a significant decrease in QOL, stressing the point that effective counseling is recommended before CaP screening and during follow-up.
Increased anxiety is common after being diagnosed with CaP. Understanding the specific domains of well-being affected by the diagnosis can help urologists mediate the negative effects This also illustrates the importance for urologists to understand the impact of CaP and its treatment on QOL so that patients can be better counseled on expectations and that care providers can provide early interventions for certain QOL domains.
Preoperative Tumor Characteristics Effect on HRQOL
Are there certain tumor parameters that help predict which patients with CaP will do better than their counterparts? Gacci et al. [25] retrospectively reviewed 595 patients who had undergone either RP or RT. Significantly better urinary function and bother scores were noted in patients with localized, low-risk CaP (cT1-2, Gleason score ≤3 + 3, and PSA ≤10 ng/mL).
Moreover, men with low clinical stage, low Gleason score, and low preoperative PSA had significantly better sexual function scores. Interestingly, there was not a statistical difference in sexual bother scores in the higher risk patients, perhaps reflecting better preoperative counseling and posttreatment expectations of sexual recovery. Moreover, biochemical recurrence also influenced urinary function and bother, as well as sexual function and bother, perhaps reflective of a general decrease in QOL after discovery of cancer recurrence.
HRQOL and Survival
It has been shown that a higher HRQOL, after controlling from clinical and demographic variables, can improve survival in several types of malignancies, including breast cancer [26] .
Aside from a better QOL, is there a similar impact in survival in patients diagnosed with CaP by merely improving QOL? Sadetsky et al. [27] This was shown by Sanda et al. [11••] , in which significant distress in the spouse was reported 1 year after initial treatment. As one would expect, the spousal group with the highest erectile dysfunction related distress was reported by 44% of partners in the RP group, 22% in the RT group, and only 13% in the BT group. Obviously, it must be noted that the RP patient group had higher baseline sexual scores and experienced the greatest decrease in QOL score, which is reflected in the spouse group. In addition, the RP group was younger and with less comorbidities and perhaps enjoying a more meaningful sexual life, which is precipitously affected immediately after surgery. Patients' reported bowel and urinary symptoms associated with spousal distress were lower and ranged from 3% to 7% in all three groups. Finally, the level of spousal distress arising from a patient's sexual and urinary symptoms after primary CaP treatment was also associated with the partner's level of satisfaction with the treatment outcome in multivariate analysis.
Clearly, a health care provider should also include the patient's partner when deciding the appropriate intervention for CaP. Similar to other studies, Badr and Taylor [29] reported that within couples, patients' and their partners' sexual function and satisfaction were very similar.
When patients had poor erectile function, their partners were more likely to report that the couple avoided open spousal discussions; this in turn was associated with partners' marital distress. Several studies have demonstrated that early intervention by the health care provider can improve QOL. Although no difference was seen between patient groups on prostate specific symptoms, spouses in the intervention group reported higher QOL, more self-efficacy, better communication, and less negative appraisal of caregiving, uncertainty, hopelessness, and symptom distress lasting up to 12 months compared with controls [30] .
Harden et al. [31] applied the Family Involvement, Optimistic Outlook, Coping Effectiveness, Uncertainty Reduction, and Symptom Management (FOCUS) program, which was originally developed for women with advanced breast cancer and their family caregivers, to prostate cancer patients and partners. Couples identified this as an opportunity to raise difficult issues they might not have discussed with their care provider, and reported high satisfaction with the program. Spouse participation in a supportive, educative intervention increased communication with their husbands, lessened their uncertainty, and reduced their negative appraisal of caregiving. Unique to CaP patients is that the vast majority of partners are women (99% in this study). Partners in this study reported more satisfaction overall than caregivers of breast cancer patients (64% were husbands). These differences may be related to the more active caregiving or illness management role that female spouses versus the supportive role caregivers (primarily husbands) of breast cancer patients assume.
HRQOL in Minority Populations
Controlling for variables, does the black population experience similar QOL compared with the white population undergoing CaP treatment? Jayadevappa et al. [32] conducted a prospective study evaluating QOL and satisfaction with care after RP or RT. Compared with white patients, black patients were less likely to choose RP as primary treatment, although when statistically controlled, ethnicity was not associated with treatment type in statistical significance.
Baseline prostate QOL scores were similar in both groups, except the black group reported higher pains in back, legs, or hips. There were a higher percentage of black men accrued from the Veterans Administration (68% vs 42%). It is unclear that this difference serves as a discrepancy in the consistency of are delivered between the two groups. The majority of white men were college educated, married, and had an annual income of >$40,000 (63% vs 22% in the black population). Outcomes of this study included the following: black men took a longer time to return to their baseline generic and sexual bother HRQOL scores; and black men reported poorer outcomes by 12 months for some generic and prostate-specific HRQOL domains, including lower 12-month scores on role physical, role emotional, bodily pain, urinary function, and urinary bother. The etiologies of these discrepancies are unknown, but perhaps it is because black patients express lower physician trust than their white counterparts [33] . Alternatively, black patients may have lower satisfaction rates with the services they receive. Regardless, this highlights the need for further research to help health care providers to be effective in improving and reducing variations in outcomes seen in the racial minority population.
Conclusions
One of the most useful papers on HRQOL in CaP was published by Sanda and associates [11••] . This prospective study of more than 1,200 patients and 625 spouses or partners serves as a landmark paper in the field and should be standard reading for any provider who counsels patients with localized prostate cancer.
QOL is affected in both the short-and long-term for men treated for CaP. QOL issues are important for treating physicians to be familiar with and understand as we strive to provide optimum care to these men and their families along the often lengthy period of the disease trajectory. A considerable impact on the QOL of patients' families is associated with definitive treatment. The mere diagnosis of CaP and AS strategies can also negatively affect patients' QOL. Therefore, the patient, spouse or partner, and physician all need to carefully consider, not only the efficacy, but also the consequences of each treatment option, including the potential adverse effects and effect on QOL. Investigations of all new and existing therapies should attempt to gather prospective and objective data on HRQOL.
